Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, a division of the company, has received a license for an additional 71 unique ovarian cancer call lines. The licensing comes from England-based Ximbio, the largest nonprofit in the world dedicated to life science reagents. TumorGenesis now has a total of 96 unique patient-derived ovarian cancer cell lines. Research such as that conducted by TumorGenesis is the foundation of preclinical research and development. “It is remarkable that the UK cancer researchers using the same media mixes now being offered by TumorGenesis for researchers around the world, independently isolated, and identified another unique set of ovarian cancer cells from patients,” said TumorGenesis president Richard Gabriel. “Adding these 71 cell lines to our existing 25 cell lines (11 of the first 25 are representative of about 95% of ovarian tumors) adds a powerful new resource for researchers. The media used to grow the novel and unique ovarian cancer cell lines, licensed by Predictive Oncology and its partner, GLG Pharma, is able to retain 95%+ of the cell’s DNA and RNA as well as crucial proteomic signatures. . . . This new media will allow researchers around the world to isolate and culture ovarian cancer cell types and, in addition, culture them reproducibly to find new targets for the diagnostics, treatment, or any other needed studies on the close interrelationship of ovarian cancer tumor populations and how they are able to fool a patient’s immune system.”
To view the full press release, visit https://ibn.fm/jWe4h
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork